Most immunosuppressive agents, including glucocorticoids, mycophenolate, methotrexate, tumor necrosis factor (TNF) inhibitors, tocilizumab, abatacept, and rituximab have been associated with poor humoral responses in patients with autoimmune diseases after SARS-CoV-2 vaccination (26–28, 32), and the highest risk has been identified with the use of rituximab (26). The gene discussed is TNF; the disease is autoimmune disease.